United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 68001-247_53e876b2-708c-9510-e063-6394a90a1372
- Product NDC
- 68001-247
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- BluePoint Laboratories
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20140313
- Source listing expiry
- 20271231
Source-listed ingredients
- ONDANSETRON — 8 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (68001-247-04) · 68001-247-04
- 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (68001-247-16) · 68001-247-16
- 30 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (68001-247-17) · 68001-247-17
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →